Mainz Biomed N.V. Ordinary Shares (MYNZ) Dividend History

Company News

• Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update

  Mainz Biomed reported a 33% increase in lab network revenue, a 30% decrease in operating loss, and an 18% decrease in net loss in 2024. The company made progress with strategic partnerships and its next-generation colorectal cancer screening product.

  GlobeNewswire Inc.

  Featured Companies: DGX TMO
• Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention

  Mainz Biomed, a molecular genetics diagnostic company, is committed to combating colorectal cancer (CRC) by advancing diagnostic solutions for early detection. The company's flagship product, ColoAlert, and its next-generation screening method, which combines mRNA biomarkers, the FIT test, and a proprietary AI algorithm, demonstrate high sensitivity and specificity for detecting advanced adenomas, highlighting the potential for early intervention and prevention.

  GlobeNewswire Inc.
• Mainz Biomed Expands into Switzerland with labor team w

  Mainz Biomed, a molecular genetics diagnostic company, has partnered with labor team, a Swiss diagnostic laboratory, to introduce its DNA-based colorectal cancer screening test, ColoAlert, to the Swiss market. The partnership aims to increase participation in early detection and prevention of colorectal cancer in Switzerland.

  GlobeNewswire Inc.
• Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population

  Mainz Biomed has launched a U.S. feasibility study, eAArly DETECT 2, to evaluate the performance of its next-generation colorectal cancer test on a large population of average-risk patients. The study aims to validate earlier results on advanced adenomas and is expected to complete enrollment in the second half of 2025, with topline results reported in the fourth quarter of the same year.

  GlobeNewswire Inc.
• Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test

  Mainz Biomed, a molecular genetics diagnostic company, has formed an agreement with Quest Diagnostics to support the commercialization of Mainz Biomed's colorectal cancer screening test, ColoAlert. Quest will provide clinical trial laboratory services and has an option to commercialize the test kit if approved by the FDA.

  GlobeNewswire Inc.

  Featured Companies: DGX